-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KsNN8m0tl+YIVWDbplL1LhId2FI7YPvQqmVwfH1qlue0YAEuWJauPjgKMw95D8i4 9bh5Y9CfMYVCovWFEM4NZw== 0000950144-07-006617.txt : 20070717 0000950144-07-006617.hdr.sgml : 20070717 20070716175727 ACCESSION NUMBER: 0000950144-07-006617 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20070716 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070717 DATE AS OF CHANGE: 20070716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDCATH CORP CENTRAL INDEX KEY: 0001139463 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 562248952 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33009 FILM NUMBER: 07982405 BUSINESS ADDRESS: STREET 1: 10720 SIKES PLACE SUITE 300 CITY: CHARLOTTE STATE: NC ZIP: 28277 BUSINESS PHONE: 7047086600 MAIL ADDRESS: STREET 1: 10720 SIKES PLACE SUITE 300 CITY: CHARLOTTE STATE: NC ZIP: 28277 8-K 1 g08383e8vk.htm MEDCATH CORPORATION MedCath Corporation
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Date of Report (Date of earliest event reported): July 16, 2007
MEDCATH CORPORATION
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation or organization)
  000-33009
(Commission File Number)
  56-2248952
(IRS Employer Identification No.)
10720 Sikes Place
Charlotte, North Carolina 28277

(Address of principal executive offices, including zip code)
(704) 708-6600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
 
 

 


TABLE OF CONTENTS

SIGNATURES
Exhibit 99.1


Table of Contents

Item 8.01 Other Events
On July 16, 2007 MedCath Corporation (MedCath or the Company) announced that the Company completed a recapitalization of its Harlingen Medical Center, located in Harlingen, Texas. Following conversion, Harlingen Medical Center is owned 36.0% by MedCath, 32.1% by Valley Baptist and 31.9% by local physician investors. Beginning with its quarterly reporting period ending September 30, 2007 MedCath will report Harlingen Medical Center as equity in net earnings of unconsolidated affiliates along with a newly formed entity, HMC Realty LLC, of which MedCath owns 36.1%. A copy of the press release is included as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
     
Exhibit    
No.   Description
     
99.1  
Press Release dated July 16, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  MEDCATH CORPORATION
 
 
Date: July 16, 2007  By:   /s/James E. Harris    
    James E. Harris   
    Executive Vice President and Chief Financial Officer   
 

 

EX-99.1 2 g08383exv99w1.htm EXHIBIT 99.1 Exhibit 99.1
 

Exhibit 99.1
(MEDCATH LOGO)
     
MEDCATH CONTACTS:
O. Edwin French
President & Chief Executive Officer
(704) 708-6600
  James E. Harris
Chief Financial Officer
(704) 708-6600
MEDCATH CORPORATION COMPLETES RECAPITALIZATION OF
HARLINGEN MEDICAL CENTER
     CHARLOTTE, N.C., July 16, 2007 — MedCath Corporation (Nasdaq: MDTH) announced today that it has completed a recapitalization of its Harlingen Medical Center, located in Harlingen, Texas.
     As part of the recapitalization, MedCath and Valley Baptist Health System, a not-for-profit health system located in Harlingen, Texas, have each elected to convert a portion of their existing debt with Harlingen Medical Center to ownership in the hospital. Following conversion, Harlingen Medical Center is owned 36.0% by MedCath, 32.1% by Valley Baptist and 31.9% by local physician investors. In addition, MedCath and Valley Baptist sponsored the formation of HMC Realty LLC. MedCath holds 36.1% and Valley Baptist holds 18.6% of HMC Realty LLC, which acquired the real property of Harlingen Medical Center. HMC Realty LLC entered into a long-term lease with Harlingen Medical Center. Long-term financing was provided to HMC Realty LLC by the Healthcare & Energy Finance group of Citicorp Leasing, Inc.
     “We’re excited to have Valley Baptist become an owner in Harlingen Medical Center as we contemplated when we restructured Harlingen Medical Center in late 2005. We look forward to working with them and our physician partners to grow and continue to provide quality care to the people in the Rio Grande Valley area of South Texas,” said Ed French, MedCath’s President and Chief Executive Officer. “Through this recapitalization we have solidified the hospital’s ownership and have greatly improved its capital structure and flexibility.”
     Valley Baptist made its convertible debt investment in Harlingen Medical Center in December 2005. “We welcomed the opportunity to convert our debt to ownership in Harlingen Medical Center earlier than we originally intended as we recognize the strategic value afforded us as equity holders in Harlingen Medical Center,” said James G. Springfield, President and Chief Executive of Valley Baptist Health System in Harlingen, Texas. “We look forward to working more closely with Harlingen Medical Center, the local physician investors and MedCath to continue Valley Baptist’s commitment to providing leading care to the local community.”

 


 

     MedCath expects that the recapitalization will be $0.02 accretive to its annual earnings per share. Beginning with its quarterly reporting period ending Sept. 30, 2007 MedCath will report the contribution from Harlingen Medical Center and HMC Realty LLC as equity in net earnings of unconsolidated affiliates. For the twelve months ended March 31, 2007, the change in reporting would have resulted in MedCath reporting lower consolidated net revenue and Adjusted EBITDA of $75.1 million and $9.9 million, respectively.
     MedCath, together with local physicians, opened Harlingen Medical Center in October 2002. The 114-bed facility includes an 18-bed Women’s Center, a 32-bed Critical Care Unit and a 64-bed Medical-Surgical Unit.
     MedCath Corporation, headquartered in Charlotte, N.C., is a healthcare provider focused on high acuity services with the diagnosis and treatment of cardiovascular disease being a primary service offering. MedCath owns interest in and operates eleven hospitals with a total of 667 licensed beds, located n Arizona, Arkansas, California, Louisiana, New Mexico, Ohio, South Dakota, and Texas. In addition, MedCath and its subsidiary MedCath Partners manage the cardiovascular program at various hospitals and provide services in diagnostics and therapeutic facilities in various states.
     Valley Baptist Health System, one of the largest and most respected integrated healthcare systems in South Texas with 850 licensed beds, has hospitals in Harlingen and Brownsville, and has been serving the Rio Grande Valley community with distinction since 1925.
# # #
     Parts of this announcement contain forward-looking statements that involve risks and uncertainties. Although management believes that these forward- looking statements are based on reasonable assumptions, these assumptions are inherently subject to significant economic, regulatory and competitive uncertainties and contingencies that are difficult or impossible to predict accurately and are beyond our control. Actual results could differ materially from those projected in these forward-looking statements. We do not assume any obligation to update these statements in a news release or otherwise should material facts or circumstances change in ways that would affect their accuracy.
     Risks and uncertainties are described in detail in “Risk Factors” in MedCath’s Registration Statement on Form S-3/A filed with the Securities and exchange Commission on March 29, 2007. A copy of this registration statement, including exhibits, is available on the internet site of the Securities and Exchange Commission at http://www.sec.gov.
     This release contains references to Adjusted EBITDA, a measure of MedCath’s projected financial performance that is not calculated and presented in conformity with generally accepted accounting principles (“GAAP”). Adjusted EBITDA represents MedCath’s income (loss) from continuing operations before interest expense; interest and other income, net; income tax expense (benefit); depreciation; amortization; share-based compensation expense; gain (loss) on disposal of property, equipment and other assets; loss on early extinguishment of debt; equity in net earnings of unconsolidated affiliates; and minority interest share of earnings of consolidated subsidiaries. MedCath’s management uses Adjusted EBITDA to measure the performance of the company’s various operating entities, to compare actual results to historical and budgeted results, and to make capital allocation decisions. Management provides Adjusted EBITDA to investors to assist them in

 


 

performing their analysis of MedCath’s historical operating results. Further, management believes that many investors in MedCath also invest in, or have knowledge of, other healthcare companies that use Adjusted EBITDA as a financial performance measure. Because Adjusted EBITDA is a non-GAAP measure, Adjusted EBITDA, as defined above, may not be comparable to other similarly titled measures of other companies.

 

GRAPHIC 3 g08383g0838300.gif GRAPHIC begin 644 g08383g0838300.gif M1TE&.#EA<@%\`/<``/(2#?ST]/:EI?5Q<_GR\OB[N_7$Q/7*ROKV]O(<&/;: MVOK1T?G5UOSQ\?63D?K9V?$5$?:^OO5*1O?EY??3T_(C(?>KJ_2(B/SZ^OC% MQ?:RLOB;F_(Y-?6AHO(Q+O:VMO-I:/(V-O(M*/6IJ?ODY/2>GO68F?K>WOC" MPO-+2/O@X/O/S_(I)O)!/O;O[OB@H?OM[?(].?B&@_(@'/O7V/2%A?>.C?)2 M4/6`?OSN[OW\_/(^//)65?:MKO5^>_).3?-<6OC.SO./CO)&1/1V=?$8%?O" MP/5Y>?OJZO(U,O%#0?CK[/-H9O)V=O$I*?BUM?-O;OOFYO*"@?%^?_(N+/WX M^/)B8?-@7O)F9?2ZN_->7/BRLO25E?5Z=_C8U_KHIO1Q;_:XN/$;&_6$@O)Y>O)$0OON[OSEY?>F MI?2"@?104?.0D/6XM?:[NO)#1?)03O1%0?-L:_K*R_(^/_1M:O>OL/O3T_>P MKOG#P_*)B?-\>_1K:?G+R_-U<_6+B_;.SO*IJ?C(R/GN[O$>&_1_@/165?:; MF_5[>_:_OO64DO)&2/:3E/>2DO6[O/.,B_GIZ?GBX_60C_6DHO)86/1=7_K) MRO)>8/;0S_BCH_WV]_2WM_1-2_.VMOGL[/CFYO.FI_-,2_1S MWOK$Q/$?(?$R,_$M,/1K;/S@W_OIZOB)A_544?:GJ/*@H/FWN/G/S_C-SOFX MM_186OG'Q_>ZN?(\//G!POKKZ_O*R?SCX_6@G_C*R?20D?C`P/2CI/>>G_.< MFO)W=_C,S/O.S?(W./O=W?B8F?)C9/)04?1G:/F_OO>TM/6NJ_.'B/5`0OO? MW_5>7/135/:#A/(/"?[^_B'Y!```````+`````!R`7P```C_`/\)'$BPH,&# M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRIO8,.*'4NVK-FS:-.J7//JW;(HYO#+CNG?J(?(8_YW'XGOO/Q$<%F-P3MD;$0G\R9]/OWY] M`+_#T"#JS#SU+N)P%0L3]A588"6J-.3%#@8V.!\5UQB%2'P.^J,(#`P1L,<1 M,50`0(4@SA?""CAY@0(@"1D1HC^#+-.1%R.8T,%D"^"4!ATKVI?(*PT)($*. M]?U1@(04.BC!0L48X(@'G0`9XH@R53%!!";0%@,_#*2XH@P=:>"+)5_HHT(F M(XBB74TW.CG?#D\T1$\1:LJ7@B1$@GAD0BIPL4.1<3;X#(\M-8`"'$00TD(2 MYKR89QSUEGAG0<]T$<+ MH_;I(`3.K/\DJ"D^:#&$$Q#8!TZ-!P601X@LO,!1+Z?\,X`LDCQ1PP>''()! M37N$T6<"IC!D0`BNEEK4A!5"L`]""T`Q@ZLK&K$2,D3P62`/#R`$@Q#`"KO1 M!0@8^\07KU"RA26VI%*3`"FXVD4#"]500;9T;JNN?0D,D&HE39(;HKDJ?8%C MA2"HX"Z\(+ZQ!4<7"#0`'+G@HX$*7V3QQ;\!]WE%NPD1<$:K:O[@C5&X5MBP M0TP,:S3[_2U,Y0[B: M1`\*&4PN'2L_1,(KR0KPPN,OC""))(ESU``R#$RN.9C&A%B!`P45XD&2:).*WP<9B%`HYG$&80(`T"\$0;8B`"7]R.(,N@ MQA?B@`Y#"$$*`?P$__P7`G#P``2[X$(O_\!$L($$@`8K2.(*U,&@"C4A'$I4 MX@/F(#<0[4@@S``$))X@!!``@8*.`YG&$\P`!"K0<8Y.T((;5E"O?P2A%3S,684J M``TPA@`+CY@#*D(DOUDLP`&L`A$+M/`"2("2(#":$8UP$D<''<,.#B)#$!!R M@1\5"``5H`*(_G@0%8Q`&7T"P!FV,`=F.$0-*\`$./H(M$H*A`1\`-(Q/(#! MC!**"#.ZAG1]#Q6+__.D$, M@CU<89,*HF,<0V)=:V50:ML@'OS#00"HQ4%XT"`/>&(%G"T0EPB"`5&,UJ_^ M@!Y!VK%:UNK5!#G:V4>^`5?L@B"W\=LM=AW4`C0,A;@&"AFW#-2""1A$IF?0 M`'1!--V!['>]_O"!<`72@&%T%V@Q>(T<JO)'A; M(25TF2!5K)"`!;+D"A6A$3T@X4`N>RJ!9('!>O7(T.23`'YP(0LN0`@)'/$D M.,/9#H9L4`A\36QAM1G1]!&*!JQLH$?_HQ:_+=`QE#N05QL(`-40R)=7+!`$ MX*#&(S"&0;P13Y"N#`-C7I%V5WU85\\Y)!0`@@>PD.J&/!A$B_J')%I6(8H= MY-B]]4`)[/N/86@Y1T+Q486&(;(CUW<@[&B0Q[2=:8%8(J$@4@(D#F)H$)T! M-:5NT,<3PNH&B;?DR/\-,DA(0`%Q.P0!^`AV@?*][Z`A!.`.FH$55,UNA`=% MX0XJH@E`+-=-#"2Z\[D!:C!=(1%`ZA];>$.(K@"/@\##;16J10;^$0=M@B@) MY4"C05!>H).OJ`C2",DL`L!2ABPA'6\X\!E@IF]^.\C?!L&Y@2!0ADQ(E2`J MX,..A6(*IQ9H('M@=GVH`*I_>.&DQ_#!';=MH!#(RP8R+Y`9J-%-3C=H3LUP MP(&+0`1<*(3L#'/8/U!?=M6[Q`L;.(,(:HP%?0SD$5(&$=X+HO<"W2`#?R^( M%0S?(*$<(6+7'L@$)%V@"F1XEP:B@GC^$0!!X%M8NUX1%10A@>Y[7P(M(+[_ M?>94`""$B`?V8"LU063V$%$Z)1/0`!?VL0,6$+EH`I&%BALD@C@DQ!F99Q\0 MT`\.11!PH'C%%Q0#<&3^\`X#P0PW<%(0P`L"@73RH70"`0@.<'W_H`W2@FPV M%@_[UR"^D"`*05&SU`\VM2+O-Q*QD4*UT`(>P`)5%2+X]P_W=D@DPB@KPB8* M80NY]RI.(!2N4(/T@0@$D2X&<@PIX`(3<%(`('D"$6K")BP94`L@F%T1,`@' M5@$HT'8($0S"5`XK&"(`\`DDT0"G$`H2\!XS$&U]!^U;(0M5AVM_@32,"''99! MS&`8B0"!61L0*(4(%"WD0Z\@P[>@3L)YG("!`)P#9(&0@`V9YEFB9 MEFHI`T9@DTJY$`@0(@WV#TF0(V_``4ECP6191!2#P MES__]09GL`C5D`>68`QI\($5D@=WA`9Z$"(7B1#]N$VL61"*21\8%A0.('[T M(59S`(]`PCP%P0!V!Y9T,IT-L@H321$>&"+YN(\'@0"!`R(Q$`L#80R0>4V. M<&,300$D^7DXL"^XT'8*6B#^UBD5@IR=%R),@`P+\07S:"#["12A@'P&7$K\C+J)Q'-@`4KP@3"B!"Q4&,M0)A?:8/>8$!'VA`P M``/7X)D%@E<"P',#<:+VD:(7,TLH$'PM.:4%L@N1!9 M"21.X'^\9X'TL0A;-P>[<'9WT`Q7^A"`>G9'@`0&,0LJ_V!^[480$2">!<(' MB;0)7Q`%/`$:FH@J#(0S-4G(@`$E(`*K%``1M"N M1L`-OH`*.*0$US4)L,"`0P"F!+&J]-&JGC,**W`"*D`#[L!/#X!Q8%:K<&H@ M'""9/<$,^>D/1>"`!K$)"XM2`):Q!%*]"N M;C`)4*`$O$!W4)<(X<4#Z[`']?\P`E`@80TRK@*1!C28A?X@""#`@(K@G091 M#Q6*7'0S(!W4`G0``HD0#:7P#\4Z'RR&$$!HF@[+$ZE0FR!Y$$LP!#OF!$M7 M$$9P8!W[3KL@J?8!`,\`1O;!E03!`#4`M/[`LP+!!2$`ATP&`))P?`["`NQ` M`G[3`%&@`FO3`Z_I($ZP!@.Q!%T03ME6M3V:;0N!#1LJ'PT+%!;K(`D0D@3! M"SCJ(,+ZBB&2M@*Q!3*[7IM'$,6``CFY7@!@#0=!`(:#;(U;>'-$!(:@LI0` M!B<@DR"""*[X#[_`C;,$*1M;(<\PM0M135H+%!&PN.R($)Z0N?/A!F(W$+!H M'ZC[#R3_X`8`%IAIFH4M.!`$D`)\"V#$.YPKH@S[,9965;SR*TS"SZ922Z[AV-94&Z(=KX#X06MP+:NP@Y? ML'QJ0@3\%`]\61_$NZ\'NB+!PG2')"^GM[_S@;<[@0FFZ@\U:A`JZB`8W#T5 ME,`%00/@%%=\<,`%D5H@*,'H6P;7ZBH7H#$+Z"2&\"Q)Z2`A/!#>QJ/C^`TF M3(\"5'&-NBA MI,9Z:G*#!D$"X!5.[.=Z"F$,'2!UV(4&K;1L.8)_>6P@>SP04>ER\J*S&\DD!%"`%@:R)U\K".6''#N(!6X40Y%4AY7P0 MF_;("V%P`+"^(>($W2`*H8@0)N!C%3)/'9!KQTRC';D0&*``F,`/$!PGT,`. M!L')GMP@`$`QU&S*UCR,<,"G]8$XZ]S*";$BX(P3`>`.[OK1'ST.1EN8*0O2 M(#W2!)$#-+$T#.;`0#;#2@D`$.O_T#%65`#VD#"`@!0.T!I``"&BJ:][@ M!D3P`V_`0<=0`8V`!0XP#E'P+"7-TN[JU!'1K9]ZLSBD#/TC[Z"I"@#R]4$LR``)Z*1"L@VA_M#(QPV0^`!YN]$#H``_"P`''P MT98`"2H``]RC$-H`5G MV06M,`1[\`.DP`[J+1'^$`)A0`:MD`3!T'@4D0SJ``%)H.0/@01U$.`P_YSG9/", M$2$!0S!B$O$*93`$9V#D,N`#/-`(=%[>$_%8+<`*P6T$5/!I/X$,5S`$JY`! M150%R`"S#_$%5_`,0I`E`D$`8P`%.W`-'QX1&?`#>O``)\``)G!+8$X*W>T% MN>`!#G#:#A$$89`"LUXO.G`+!5`)1=`$%>$/4(`"S;``F,"8$2X1/=`*/W`# M5U#/\\,)X^T//(`"W3V+$.'HD`X1)U`&2D`)8T!""+`--5`$P$L1$@`?K0#D M8U4`2="D/X$)(:`.=BT1#5`.5-`$]?P`RL`#'R,1$3`$_?4*=N"'$]$(NB@0 MF?`&Z&5P!3O`!@4>`*SP!D7/$P2@"ZW@ MZA4!#_(P!#9/$&Q`!38P$1D_70VP`2P`"Q3!`E,@$,5P#A6`"IR-I8H0C+W" M`/Y0`A3A#W?`3\6P"YU`!.$.$3T0#/00`-^0!-AN$?Z``Q+:Z35?XD7MPP5A M`/[`!BK?Z`Z0`;O`4,^2`PZ`]4"A`#M@]QH!":1`@0CQ`1YPM0X1`3]P!-\0 M#SY`"F$P[Q!Q#%B@#NK`!EV^"<'=$`P0`P[0#!D=]Q/A#W70`[)0`Q[0"MSP MYP-`!<*@#I[@!%3_@.X/X0\.HIT1P-#B0G\\ M?OP`]P?4G(L7@[QAA>2BORDA0_KK509*1*F9C1]YKP%!'4"EC<_@3=:3"E"AY M9UT@):5O"3"=$J-5)90HVI%,5(AMZF.6103^F"`3ZR7&T'_M>`!9X!5L_U[< M>5W7,)E[("12=,XR[$?%QMA'A-35DQFF<#$W0NB'@1IN\^W` MHA#@X;OPT\\>7PM!*`Z&Q",!A!Q07:@"* M"NR!*JR1]@@O"B*&$`,(`Q'T,J0.J*"$@2)U0`"&%,.J8@\.@EE`O8&J..$" M#EB)3"QU$)'EGV38\2"7X:C*83L2?0LS#$F*_/^GB@=6*4(:M#[PAP!F$-#" M@VP472H((+J(;R!F".BDB4C]B23-L;)X"ZTMP-'B&Y`(2J:<(J309ZP,.#"B MH&_^F.&-+K\45B$$=J&"#G6<<::`$8!A3:PYN$A""0LD<<>(7K"(X0@\T(HG M&`W^8<:`)$BA0"P8LHBNQ%U"2$2=#%[Q)A(ZH(&EO+'N\(>@#Y*XXAL=J&I@ M%40L8,@*)S1=2M]=\RJ!!;C$(D#:-S!QYI57C/"C@GL;I.H:$1H>J!@'6/`G MV&%3_H<`*2KP!X(BCO'GC2#00J*.3OP!H!$`CBEBDM[&DF&("`9*Q@\64@KK MYG5](R"7$/SI)!J7*Y#_PH6\IMB7H$\@P`%.LLC@81N&X/`GEK&T%GFLAR,6 MBY,2@GDYFFC\\0<6K-%Z>.U_O('B9)4#+X@`+^K(Q99-)O`M%E$:EU%PR']" MP(O&14D#W\@SUQPM#%2I7)2\-Q=]=-)+-_UTU%-7?7766W?]==ACUQR-6(:Q M_7;<<]=]=]Y[]_UWX(,7?GCBBS?^>.235WYYYG5'6_:"RLB'&.JKM_YZ[+/7 M?GONN_?^>_##%W]\\LLW_WSTTUT2@=_]]^..7?W[ZZ[?_?OSSUW]__OOW M_W\`!E"``R1@`0UX0`0F4($+9&`#'?A`"$90@A.D8`4M>$$,9E"#&^1@!SWX M-T$0AE"$(R1A"4UX0A2F4(4K9&$+7?A"&,90AC.D80UM>$,
-----END PRIVACY-ENHANCED MESSAGE-----